Bridgewater Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Bridgewater Advisors's REGN Position: Q2 2026 in Review
Bridgewater Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 6.6% in Q2 2026, buying an estimated $14.3K and bringing the position to 340 shares worth $252K. The position accounts for 0.01% of the portfolio, ranked #417.
Bridgewater Advisors first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Bridgewater Advisors held 340 shares of Regeneron Pharmaceuticals worth $252K as of Q2 2026.
- Bridgewater Advisors bought 21 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $14.3K.
- Regeneron Pharmaceuticals made up 0.01% of Bridgewater Advisors's portfolio in Q2 2026, its #417 holding.
- Bridgewater Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Bridgewater Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.